叮噹健康旗下藥房首發上架新藥艾維達,持續發展“生命方舟計劃”
6月10日, 叮噹健康旗下北京地區藥房上架1類新藥注射用瑞康曲妥珠單抗(艾維達),爲相關腫瘤患者提升用藥可及性和便利性。當日13:38完成店內首單。
資料顯示,艾維達由恆瑞醫藥子公司蘇州盛迪亞生物醫藥有限公司自主研發,適用於治療存在 HER2(ERBB2)激活突變且滿足一定前置條件的局部晚期或轉移性非小細胞肺癌(NSCLC)成人患者。
叮噹健康作爲即時健康到家企業,圍繞腫瘤、自免、神經系統等疾病領域持續加強新特藥品類佈局。今年4月,叮噹健康旗下藥房上架阿爾茨海默病藥品記能達?,助力破解AD患者的“記憶困局”。
叮噹健康相關負責人介紹:“爲了提升各類新特藥的可及性,公司將持續推進新特藥‘生命方舟計劃’,一方面將積極深化藥企合作,加強新特藥品類佈局,另一方面還將不斷強化智慧用藥提醒以及全病程健康管理、冷鏈到家等專業健康服務,爲患者打通新特藥‘到家最後一公里’”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.